Glaxo fields big H1N1 vax orders as Vical starts testing

GlaxoSmithKline has already received orders for 128 million doses of a new swine flu vaccine that has yet to be developed. And the pharma giant says that it expects many, many more requests before it's all over.

"I fully anticipate that we will receive significantly more orders in the coming weeks and months," Chief Executive Andrew Witty told shareholders at an annual meeting. The UK, France, Belgium and Finland have placed the orders to date.  GSK says that it expects to start production on a new vaccine soon after it gets seed stock.

Glaxo has already offered the WHO 50 million doses of a new vaccine for free distribution in poor countries and says it will discount its vaccine price for developing nations.

- read the report from Reuters
- and read the story from the AP

ALSO: Vical says that it has already developed a prototype vaccine and proceeded to animal testing. The developer assumes that the preclinical study will be positive and is ready to initiate a human study with the U.S. Navy. Report

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.